Globus Medical, Inc. (GMED): Price and Financial Metrics

Globus Medical, Inc. (GMED): $51.65

0.25 (+0.49%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

GMED Price/Volume Stats

Current price $51.65 52-week high $62.88
Prev. close $51.40 52-week low $43.38
Day low $51.58 Volume 1,695,000
Day high $53.58 Avg. volume 1,230,783
50-day MA $54.08 Dividend yield N/A
200-day MA $53.29 Market Cap 6.99B

GMED Stock Price Chart Interactive Chart >

GMED POWR Grades

  • GMED scores best on the Quality dimension, with a Quality rank ahead of 72.7% of US stocks.
  • GMED's strongest trending metric is Quality; it's been moving down over the last 26 weeks.
  • GMED's current lowest rank is in the Stability metric (where it is better than 18.03% of US stocks).

GMED Stock Summary

  • GMED's current price/earnings ratio is 45.32, which is higher than 84.43% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for GMED is currently 35.28, higher than 89.01% of US stocks with positive operating cash flow.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.19 for GLOBUS MEDICAL INC; that's greater than it is for only 12.56% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GLOBUS MEDICAL INC are WST, DHX, MTRN, ASH, and GNRC.
  • GMED's SEC filings can be seen here. And to visit GLOBUS MEDICAL INC's official web site, go to www.globusmedical.com.

GMED Valuation Summary

  • GMED's EV/EBIT ratio is 43.5; this is 197.95% higher than that of the median Healthcare stock.
  • GMED's price/sales ratio has moved up 2.6 over the prior 139 months.

Below are key valuation metrics over time for GMED.

Stock Date P/S P/B P/E EV/EBIT
GMED 2023-12-29 6.0 1.8 46.5 43.5
GMED 2023-12-28 6.1 1.8 47.1 44.1
GMED 2023-12-27 6.0 1.7 46.4 43.4
GMED 2023-12-26 6.1 1.8 47.2 44.1
GMED 2023-12-22 6.0 1.8 46.8 43.8
GMED 2023-12-21 6.1 1.8 47.1 44.0

GMED Growth Metrics

    Its 2 year price growth rate is now at 28.08%.
  • The 2 year revenue growth rate now stands at 21.22%.
  • The 3 year net cashflow from operations growth rate now stands at 52.71%.
Over the past 49 months, GMED's revenue has gone up $305,301,000.

The table below shows GMED's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 998.366 190.746 155.211
2022-06-30 973.939 235.088 154.991
2022-03-31 961.307 257.394 141.946
2021-12-31 958.102 276.274 149.191
2021-09-30 941.526 280.205 187.042
2021-06-30 927.903 256.191 184.047

GMED's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GMED has a Quality Grade of B, ranking ahead of 90.91% of graded US stocks.
  • GMED's asset turnover comes in at 0.547 -- ranking 84th of 186 Medical Equipment stocks.
  • OFIX, SRTS, and ESMC are the stocks whose asset turnover ratios are most correlated with GMED.

The table below shows GMED's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.547 0.745 0.189
2021-03-31 0.514 0.729 0.131
2020-12-31 0.512 0.724 0.111
2020-09-30 0.510 0.732 0.103
2020-06-30 0.504 0.741 0.096
2020-03-31 0.542 0.764 0.165

Globus Medical, Inc. (GMED) Company Bio


Globus Medical focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company was founded in 2003 and is based in Audubon, Pennsylvania.


GMED Latest News Stream


Event/Time News Detail
Loading, please wait...

GMED Latest Social Stream


Loading social stream, please wait...

View Full GMED Social Stream

Latest GMED News From Around the Web

Below are the latest news stories about GLOBUS MEDICAL INC that investors may wish to consider to help them evaluate GMED as an investment opportunity.

4 Orthobiologic Stocks Set To Soar In 2024

Welcome to the transformative landscape of orthobiologics, where cutting-edge treatments utilize the body's own cells and healing factors to reverse orthoarthritis effects and expedite recovery fro...

Yahoo | December 19, 2023

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.

Yahoo | December 15, 2023

3 Stocks at the Forefront of Medical Robotics

Every now and then, speculation – within carefully defined limits – may be appropriate, which brings us to the case for medical robotics stocks to buy.

Josh Enomoto on InvestorPlace | December 10, 2023

Globus Medical (GMED) Down 3.1% Since Last Earnings Report: Can It Rebound?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 7, 2023

Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Yahoo | December 7, 2023

Read More 'GMED' Stories Here

GMED Price Returns

1-mo -4.03%
3-mo -0.27%
6-mo -2.29%
1-year -0.35%
3-year -14.59%
5-year 7.92%
YTD -3.08%
2023 -28.25%
2022 2.87%
2021 10.70%
2020 10.77%
2019 36.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!